UK +44 (0) 203 929 0534 | US +1 (917) 297-6587

Lifecycle Management & Legacy Strategy

How do we improve diagnosis of atrial fibrillation globally to maximise our drug’s end-of-life sales?

We were tasked with helping our client, a world-leading pharmaceutical company, design screening programs capable of increasing the global diagnosis of atrial fibrillation.

We evaluated previous screening programs to see what had been most successful across the US, Canada and Europe, designing a global playbook of market-specific strategies and working with Global and affiliates to test these strategies and begin implementation.

< Previous Case Study

Next Case Study >

Home                  Expertise                   Our Team                   Join us                    Contact us

Brand & Website design by GeoMedia           Privacy Policy

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Home                  Expertise                   Our Team                   Join Us                    Contact Us

Home                  Expertise                   Our Team
Join Us                    Contact Us

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

© 2019 Eradigm Limited, Registered England & Wales, No. 10491826
New Derwent House, 69-73 Theobalds Road, London, WC1X 8TA

Brand & Website design by GeoMedia          Privacy Policy